Anti-PEG antibody bioanalysis: A clinical case study with PEG-IFN-λ-1a and PEG-IFN-α2a in naive patients

Bioanalysis

Volumn 7, Issue 9, 2015, Pages 1093-1106

  Myler, Heather ^a   Hruska, Matthew W ^a   Srinivasan, Subasree ^a   Cooney, Elizabeth ^a   Kong, George ^a   Dodge, Robert ^a   Krishna, Murli ^a   Zhu, Jie ^b   Felix, Tonya ^c   Gleason, Carol ^a   Piccoli, Steven P ^a   Desilva, Binodh ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b WUXI APPTEC   (China)

^c LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; DRUG ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERFERON ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON LAMBDA; PEGYLATED ANTIBODY; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; CD79B ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; MACROGOL DERIVATIVE;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CONTROLLED STUDY; CROSS REACTION; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INNATE IMMUNITY; MACACA FASCICULARIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SEROCONVERSION; TREATMENT OUTCOME; VALIDATION PROCESS; BLOOD; CHEMISTRY; CONFORMATION; HEPATITIS C; IMMUNOLOGY; PROCEDURES; REPRODUCIBILITY;

CROSS REACTIONS; HEPATITIS C; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN M; IMMUNOGLOBULINS; INTERFERON-ALPHA; MOLECULAR CONFORMATION; POLYETHYLENE GLYCOLS; REPRODUCIBILITY OF RESULTS;

EID: 84930606882     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.36     Document Type: Article

References (18)

1. Sailstad JM, Amaravadi L, Clements-Egan A et al. A white paper-consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J. 16(3), 488-498 (2014).
2. Parenky A, Myler H, Amaravadi L et al. New FDA draft guidance on immunogenicity. AAPS J. 16(3), 499-503 (2014).
3. Stevenson L, Amaravadi L, Myler H et al. LM by LBA and immunogenicity. Bioanalysis 6(24), 3355-3368 (2014).
4. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research. Guidance for industry: immunogenicity assessment for therapeutic protein products. FDA, Rockville, MD, USA (2014). www.fda.gov
5. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research. Draft guidance for industry: assay development for immunogenicity testing of therapeutic proteins. FDA, Rockville, MD, USA (2009). www.fda.gov
6. Garay RP, El-Gewely R, Armstrong JK et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Del. 9(11), 1319-1323 (2012).
7. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm. Res. 30, 1729-1734 (2013).
8. Liu Y, Reidler H, Pan J et al. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. J. Pharmacol. Toxicol. Meth. 64(3), 238-245 (2011).
9. Armstrong JK, Hempel G, Koling S et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110, 103-111 (2007).
10. Ganson NJ, Kelly SJ, Scarlett E et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a Phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther. 8(R12), 1-10 (2006).
11. Hershfield MS, Ganson NJ, Kelly SJ et al. Induced and preexisting anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res. Ther. 16(R63), 2-11 (2014).
12. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4(1), 63-68 (2003).
13. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4(1), 69-77 (2003).
14. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 79(6), 3851-3854. (2005).
15. Doyle SE, Schreckhise H, Khuu-Duong K et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44(4), 896-906 (2006).
16. Myler H, Felx T, Zhu J et al. Measuring biotherapeutics with endogenous counterparts and pre-existing antibodies: an interferon case study. Bioanalysis 6(8), 1113-1122 (2014).
17. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharma. Biomed. Anal. 48 (2008) 1267-1281.
18. Krishna M, Palme H, Duo J et al. Development and characterization of antibody reagents to assess anti PEG IgG antibodies in clinical samples. Bioanalysis (In Press).